IRIS - Res&Arch Institutional Research Information System - Research & Archive

METRO, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 917
EU - Europa 581
AS - Asia 424
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 1
Totale 1.925
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 914
IE - Irlanda 201
IT - Italia 194
SG - Singapore 172
HK - Hong Kong 96
CN - Cina 80
VN - Vietnam 57
RO - Romania 41
DE - Germania 37
FI - Finlandia 27
RU - Federazione Russa 24
FR - Francia 19
UA - Ucraina 14
KR - Corea 11
CH - Svizzera 4
GB - Regno Unito 4
CZ - Repubblica Ceca 3
NL - Olanda 3
SE - Svezia 3
AT - Austria 2
CA - Canada 2
EU - Europa 2
IN - India 2
PL - Polonia 2
TR - Turchia 2
UZ - Uzbekistan 2
CL - Cile 1
GR - Grecia 1
HU - Ungheria 1
LB - Libano 1
MX - Messico 1
PH - Filippine 1
RS - Serbia 1
Totale 1.925
Salva come PNG Salva come JPEG
Città #
Chandler 245
Dublin 201
Singapore 143
Hong Kong 96
Perugia 94
Boardman 86
San Mateo 66
Dong Ket 57
Santa Clara 56
Altamura 50
Bucharest 41
Lawrence 38
Medford 38
Princeton 38
Beijing 30
Redmond 20
Wilmington 20
Munich 18
Helsinki 16
Andover 14
San Paolo di Civitate 11
Seoul 11
Saint Petersburg 10
Arezzo 7
Dallas 7
Los Angeles 6
Redwood City 6
Norwalk 5
Ann Arbor 4
Nanjing 4
New York 4
Brno 3
Des Moines 3
Falls Church 3
Houston 3
Rome 3
Simi Valley 3
Woodbridge 3
Guangzhou 2
Izmir 2
Kansas City 2
Paris 2
Terni 2
Amelia 1
Amsterdam 1
Angeles 1
Aprilia 1
Ashburn 1
Asso 1
Azcapotzalco 1
Baoding 1
Bologna 1
Cambridge 1
Catania 1
Changsha 1
Chaoyang 1
Chengdu 1
Chicago 1
Dearborn 1
Den Haag 1
Esslingen am Neckar 1
Fairfield 1
Falkenstein 1
Frankfurt am Main 1
Guttingen 1
Kiev 1
Kunming 1
Lappeenranta 1
Milan 1
Mumbai 1
Nagold 1
Nuremberg 1
Nürnberg 1
Ottawa 1
Pullach im Isartal 1
Springfield 1
Sterling 1
Szeged 1
Tianjin 1
Trevi 1
Vienna 1
Totale 1.511
Salva come PNG Salva come JPEG
Nome #
Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications 145
Gene identification for risk of relapse in stage I lung adenocarcinoma patients: A combined methodology of gene expression profiling and computational gene network analysis 77
Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series 73
Prognostic implication of aquaporin 1 overexpression in resected lung adenocarcinoma 68
Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib 61
New somatic TERT promoter variants enhance the Telomerase activity in Glioblastoma 61
Anaplastic lymphoma kinase immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients. 59
Targeting the KRAS variant for treatment of non-small cell lung cancer: Potential therapeutic applications 54
Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations 54
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer 53
Sacrum colon-rectal cancer metastasis: Microwave ablation for palliative pain treatment 52
CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles 51
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool 51
How might treatment of ALK-positive non-small cell lung cancer change in the near future? 50
Inflammatory markers as prognostic factors of survival in patients affected by hepatocellular carcinoma undergoing transarterial chemoembolization 50
Precision medicine against ALK-positive non-small cell lung cancer: beyond crizotinib 50
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 50
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy 50
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients 50
Osimertinib 48
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence 47
Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland 45
Fatal acute disseminated intravascular coagulation as presentation of advanced ALK-positive non-small cell lung cancer: Does oncogene addiction matter? 45
MiRNAs and resistance to EGFRâ€"TKIs in EGFR-mutant non-small cell lung cancer: Beyond 'traditional mechanisms' of resistance 44
Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 >= 50% who progress on first-line immunotherapy: real-world data from a European cohort 44
Successful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer Patient. 43
Higher tlr7 gene expression predicts poor clinical outcome in advanced nsclc patients treated with immunotherapy 41
Survival outcomes and incidence of brain recurrence in high-grade neuroendocrine carcinomas of the lung: Implications for clinical practice 40
Targeting EGFR and ALK in NSCLC: current evidence and future perspective 40
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM) 36
Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy 35
Brigatinib for anaplastic lymphoma kinase-tyrosine kinase inhibitor naïve anaplastic lymphoma kinase-positive advanced non-small cell lung cancer: An effective but still broken option 33
Efficacy of Pembrolizumab Monotherapy in Patients with or without Brain Metastases from Advanced Non-Small Cell Lung Cancer with a PD-L1 Expression ≥50% 33
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab 31
Prognostic role of expression levels of FABP3 and AKR1B10 genes in adenocarcinoma stage I patients. 30
Detection of egfr mutations in plasma cell-free tumor dna of tki-treated advanced-nsclc patients by three methodologies: Scorpion-arms, pnaclamp, and digital pcr 30
Tumour infiltrating lymphocytes (TILs) and PD-L1 expression in malignant pleural mesothelioma. 29
Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations 29
Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma 28
Early stage resectable non-small cell lung cancer: Is neoadjuvant immunotherapy the right way forward? 22
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer 22
2356P The role of pathological features in predicting prognosis of patients with advanced RET-positive NSCLC 15
Abstract 5134: Immunohistochemistry expression of membrane targets for novel therapeutic agents in RET-rearranged NSCLC 14
Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer 13
Lorlatinib beyond progression plus platinum/pemetrexed for ALK-positive non-small cell lung cancer patients: report of two cases 13
Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience 12
Assessment of TILs, IDO-1 and PD-L1 in resected non small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. 12
Correction: Repotrectinib’s Clinical Benefit and Its Brain Penetration in a Patient with Meningeal Carcinomatosis from G2032R-Mutated ROS-1 Positive Non-Small Cell Lung Cancer (Oncology and Therapy, (2024), 12, 1, (163-171), 10.1007/s40487-023-00251-6) 12
P1.22-19 Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions 11
Totale 2.056
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.458
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.458
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202081 0 0 0 0 3 3 6 3 12 42 12 0
2020/2021164 3 0 2 19 59 4 0 7 4 6 3 57
2021/2022322 6 48 2 3 3 3 1 94 23 31 44 64
2022/2023712 39 155 11 54 68 58 0 25 270 2 25 5
2023/2024367 15 28 21 7 2 3 92 10 21 10 76 82
2024/2025276 19 70 57 41 89 0 0 0 0 0 0 0
Totale 2.056